Affimed NV Company Profile (NASDAQ:AFMD)

About Affimed NV

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: AFMD
CUSIP:

Key Metrics:

Previous Close: $2.73
50 Day Moving Average: $2.78
200 Day Moving Average: $3.28
52-Week Range: $2.34 - $8.42
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.55
P/E Growth: 0.00
Market Cap: $93.76M
Outstanding Shares: 33,487,000
Beta: 3.73

Profitability:

Net Margins: -440.97%
Return on Equity: -49.84%
Return on Assets: -42.35%

Debt:

Debt-to-Equity Ratio: 0.04%
Current Ratio: 8.73%
Quick Ratio: 8.70%

Additional Links:

Companies Related to Affimed NV:

Consensus Ratings for Affimed NV (NASDAQ:AFMD) (?)

Ratings Breakdown:	2 Hold Ratings, 4 Buy Ratings
Consensus Rating:	Buy (Score: 2.67)
Consensus Price Target:	$9.60 (251.65% upside)

Analysts' Ratings History for Affimed NV (NASDAQ:AFMD)

Show:

Date	Firm	Action	Rating	Price Target
8/12/2016	Leerink Swann	Downgrade	Outperform -> Market Perform	$8.00 -> $3.00
8/9/2016	Jefferies Group	Reiterated Rating	Hold
5/18/2016	Wells Fargo & Co.	Reiterated Rating	Buy
4/11/2016	BMO Capital Markets	Initiated Coverage	Outperform	$7.00
12/10/2015	Laidlaw	Initiated Coverage	Buy	$15.00
11/20/2015	Oppenheimer Holdings Inc.	Reiterated Rating	Outperform	$19.00

(Data available from 9/30/2014 forward)

Earnings History for Affimed NV (NASDAQ:AFMD)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/5/2016
8/10/2016	Q216	($0.22)	($0.27)	$2.10 million	$2.07 million	View	Listen
5/18/2016	Q116	($0.17)	($0.25)	$1.88 million	$1.90 million	View	Listen
3/30/2016	Q415	($0.18)	($0.22)	$1.71 million	$1.66 million	View	Listen
11/10/2015	Q315	($0.25)	($0.24)	$1.87 million	$1.20 million	View	Listen
8/4/2015	Q215	($0.14)	($0.21)	$2.56 million	$2.21 million	View	N/A
5/21/2015	Q115	($0.14)	($0.07)			View	Listen
3/25/2015	Q414	($0.33)	($0.22)			View	N/A
11/18/2014	Q314	($0.33)	$2.69			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Affimed NV (NASDAQ:AFMD)

Current Year EPS Consensus Estimate: $-1.08 EPS
Next Year EPS Consensus Estimate: $-1.07 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.28)	($0.28)	($0.28)
Q2 2016	2	($0.29)	($0.14)	($0.22)
Q3 2016	2	($0.29)	($0.23)	($0.26)
Q4 2016	3	($0.30)	($0.19)	($0.24)

(Data provided by Zacks Investment Research)

Dividend History for Affimed NV (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Affimed NV (NASDAQ:AFMD)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Affimed NV (NASDAQ:AFMD)

Date	Headline
	Penny Stock Investors are Growing Curious About Affimed N.V. (NASDAQ:AFMD) - Duncan Research (NASDAQ:AFMD) www.duncanindependent.com - September 30 at 8:14 AM
	Affimed to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology (NASDAQ:AFMD) www.publicnow.com - September 22 at 8:58 AM
	Affimed to Present at Upcoming Investor Conferences (NASDAQ:AFMD) www.publicnow.com - September 1 at 11:49 AM
	Affirmed Therapeutics BV (NASDAQ: AFMD) announces quarterly earnings - BNB Daily (blog) (NASDAQ:AFMD) www.baseball-news-blog.com - August 11 at 3:23 PM
	Affirmed Therapeutics reports 2Q loss (NASDAQ:AFMD) www.cnbc.com - August 10 at 12:41 PM
	Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update (NASDAQ:AFMD) www.publicnow.com - August 10 at 12:41 PM
	Affimed Announces Second Quarter 2016 Financial Results and Corporate Update Conference Call (NASDAQ:AFMD) www.publicnow.com - August 3 at 11:55 AM
	Affimed N.V. (NASDAQ:AFMD) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:AFMD) www.engelwooddaily.com - June 30 at 3:23 PM
	Affimed NV (NASDAQ: AFMD) Set To Develop Clinical Candidate is AFM13 - Scibility Media (NASDAQ:AFMD) scibilitymedia.com - June 29 at 3:19 PM
	Strong Sell Calls Recommendations For Affimed N.V. (NASDAQ:AFMD) At 0 - Investor Newswire (NASDAQ:AFMD) www.investornewswire.com - June 27 at 8:07 AM
	Affimed NV (NASDAQ:AFMD) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:AFMD) www.engelwooddaily.com - June 23 at 10:47 PM
	Affimed NV (NasdaqGM:AFMD) Stock Momentum Hits EXTREME Weakness - CML News (NASDAQ:AFMD) news.cmlviz.com - June 22 at 3:20 PM
	Strong Buy Calls Count For Affimed N.V. (NASDAQ:AFMD) At 3 - Investor Newswire (NASDAQ:AFMD) www.investornewswire.com - June 20 at 9:52 AM
	Trend Of Rating Given To Affimed N.V. (NASDAQ:AFMD) - Investor Newswire (NASDAQ:AFMD) www.investornewswire.com - June 12 at 8:40 PM
	Affimed N.V. (NASDAQ:AFMD) Dropped-9.07%: Verizon Communications Inc. (NYSE:VZ), Del Frisco's Restaurant ... - KC Register (NASDAQ:AFMD) www.kcregister.com - June 10 at 3:23 PM
	Stock Review and Earnings Check on Affimed N.V. (NASDAQ:AFMD) - HNN (NASDAQ:AFMD) hintsnewsnetwork.com - June 3 at 11:50 AM
	These 7 Stocks Under $10 Are About to Break Out (NASDAQ:AFMD) www.thestreet.com - June 3 at 7:55 AM
	Target Price and Stock Performance Rundown for Affimed N.V. (NASDAQ:AFMD) - HNN (NASDAQ:AFMD) hintsnewsnetwork.com - June 1 at 3:23 PM
	Affimed N.V. (NASDAQ:AFMD) Stock Update & Estimates - Stock Tick Tock (NASDAQ:AFMD) www.stockticktock.com - June 1 at 11:42 AM
	Affimed to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:AFMD) www.publicnow.com - May 31 at 5:22 AM
	Affimed NV (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Let Me Know About This (NASDAQ:AFMD) www.lmkat.com - May 30 at 9:52 PM
	Earnings Review and Stock Rundown for Affimed N.V. (NASDAQ:AFMD) - Wall Street Hints and News (NASDAQ:AFMD) hintsnewsnetwork.com - May 28 at 2:46 PM
	Leerink Swann Downgrades Affimed NV to Market Perform - Trade Calls (NASDAQ:AFMD) www.tradecalls.org - May 26 at 2:50 PM
	Affimed Announces Annual General Meeting of Shareholders (NASDAQ:AFMD) www.publicnow.com - May 24 at 4:16 AM
	Affimed Therapeutics downgraded by Leerink Partners (NASDAQ:AFMD) finance.yahoo.com - May 19 at 9:17 AM
	Affimed Reports Financial Results for First Quarter 2016 (NASDAQ:AFMD) www.publicnow.com - May 18 at 7:52 AM
	Q1 2016 Affimed NV Earnings Release - Time Not Supplied (NASDAQ:AFMD) biz.yahoo.com - May 18 at 7:07 AM
	Affimed to Present at the UBS Global Healthcare Conference -- New York (NASDAQ:AFMD) finance.yahoo.com - May 17 at 5:00 AM
	Affimed Announces First Quarter 2016 Financial Results and Corporate Update Conference Call (NASDAQ:AFMD) www.publicnow.com - May 11 at 5:22 AM
	ETF’s with exposure to Affimed NV : May 5, 2016 (NASDAQ:AFMD) www.capitalcube.com - May 5 at 4:48 PM
	Affimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the AACR Annual Meeting 2016 (NASDAQ:AFMD) www.publicnow.com - April 21 at 5:17 AM
	Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016 (NASDAQ:AFMD) www.publicnow.com - April 21 at 5:17 AM
	Affimed NV (AFMD): Samuel Isaly Unloads Shares of Sinking Stock (NASDAQ:AFMD) feedproxy.google.com - March 31 at 8:32 PM
	Are Analysts Bearish Affimed NV (NASDAQ:AFMD) After Last Week? - RiversideGazette.com (NASDAQ:AFMD) www.riversidegazette.com - February 26 at 12:52 PM
	Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy (NASDAQ:AFMD) finance.yahoo.com - February 22 at 5:00 AM
	Affimed NV (NASDAQ:AFMD) Shorted Shares Increased 28.98% After Market Selling - fdanewsalert.com (NASDAQ:AFMD) www.fdanewsalert.com - February 14 at 2:25 PM
	Affimed NV (NASDAQ:AFMD) Shorted Shares Increased By 26.79% - fdanewsalert.com (NASDAQ:AFMD) www.fdanewsalert.com - February 5 at 2:35 PM
	Affimed N.V. (NASDAQ:AFMD): Quarterly Earnings Update - Investor Newswire (NASDAQ:AFMD) www.investornewswire.com - February 4 at 2:30 PM
	Affimed to Present at the Leerink Partners 5th Annual Global Healthcare Conference (NASDAQ:AFMD) finance.yahoo.com - February 4 at 5:00 AM
	Affimed N.V. (NASDAQ:AFMD) Analyst Rating Update - Investor Newswire (NASDAQ:AFMD) www.investornewswire.com - January 30 at 1:38 PM
	Affimed N.V. (NASDAQ:AFMD) Short Interest Update - WallStreet Prudent (NASDAQ:AFMD) www.wallstreetprudent.com - January 28 at 1:51 PM
	Company Shares of Affimed NV (NASDAQ:AFMD) Rally 1.65% - WallStreet Prudent (NASDAQ:AFMD) www.wallstreetprudent.com - January 24 at 7:36 PM
	Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board (NASDAQ:AFMD) www.noodls.com - January 21 at 10:06 AM
	10:00 am Affimed Therapeutics names Dr. Joerg Windisch as COO (NASDAQ:AFMD) finance.yahoo.com - January 21 at 10:00 AM
	Affimed to Host Hodgkin’s Lymphoma Day with Key Opinion Leaders on January 26th in New York (NASDAQ:AFMD) www.noodls.com - January 20 at 5:25 AM
	Affimed to Host Hodgkin's Lymphoma Day with Key Opinion Leaders on January 26th in New York City (NASDAQ:AFMD) finance.yahoo.com - January 20 at 5:00 AM
	Affimed N.V. (NASDAQ:AFMD) - Stock Sentiment And ABR Update - Investor Newswire (NASDAQ:AFMD) www.investornewswire.com - January 18 at 7:39 PM
	Analysts Review: Affimed NV - iStreetWire (NASDAQ:AFMD) www.istreetwire.com - January 18 at 12:12 PM
	Why Biotech Affimed N.V. Should Be On Your Radar (NASDAQ:AFMD) www.investopedia.com - December 8 at 8:00 AM
	Affimed Presents Data Comparing T-cell- and NK-cell-engaging TandAbs AFM11 and AFM12 at ASH (NASDAQ:AFMD) www.noodls.com - December 6 at 9:29 AM